Company Profile
Cue Biopharma Inc Stock Price, News & Analysis
- Ticker:
- CUE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
30.25 USD (-7.12%)
Close
Last updated: July 28, 2026
116M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, CUE closed down 7.12% at $30.25. No new same-company headline was identified in the current news window.
Company overview
Business overview
Cue Biopharma is a biotechnology company focused on selective immunotherapy and controlled T-cell activation. Its story is built around creating more precise anti-cancer immune responses through engineered biology.
Geographic Base and Sector Classification
Cue Biopharma is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology and immunology biotechnology.
Business Model Characteristics
The company depends on clinical data, translational validation, and capital discipline while it develops a narrow pipeline. Investors usually follow early readouts and platform differentiation.
Position Within the Biotechnology Landscape
Cue occupies a specialized immunotherapy niche within biotech. The stock is sensitive to whether its T-cell platform can show enough clinical differentiation to matter.
Future catalysts
Cue Health is now a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a live diagnostic milestone. The market is focused on residual value.
Recent news
- 01
- 02
Cue Biopharma Announces $50.0 Million Private Placement
Source: Cue Biopharma Inc
- 03
- 04
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Source: Cue Biopharma Inc
- 05
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Source: Cue Biopharma Inc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cue Biopharma Inc (CUE)?
Cue Biopharma Inc (CUE) most recently closed at 30.25 USD, a -7.12% move versus the previous session.
What is the market cap of Cue Biopharma Inc (CUE)?
Cue Biopharma Inc currently has a market capitalization of 116M USD on BioPharmSignal.
What does Cue Biopharma Inc do?
Cue Biopharma is a biotechnology company focused on selective immunotherapy and controlled T-cell activation. Its story is built around creating more precise anti-cancer immune responses through engineered biology.
On which exchange is CUE stock listed?
Cue Biopharma Inc (CUE) is associated with NASDAQ, United States, Biopharma.
What is Biopharma?
Cue Biopharma is a biotechnology company focused on selective immunotherapy and controlled T-cell activation.
Which conditions is Cue Biopharma Inc targeting with Biopharma?
Cue Biopharma Inc is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Cue Biopharma Inc describe recent progress with Biopharma?
Cue Health is now a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a live diagnostic milestone. The market is focused on residual value.
What is T-cell?
Cue Biopharma is a biotechnology company focused on selective immunotherapy and controlled T-cell activation.